NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01, FiscalAI reports. The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $25.57 million.
NRx Pharmaceuticals Stock Performance
NRx Pharmaceuticals stock traded up $0.07 during trading on Friday, reaching $3.28. The company had a trading volume of 2,216,622 shares, compared to its average volume of 1,224,002. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $3.84. The firm has a market capitalization of $108.47 million, a price-to-earnings ratio of -2.36 and a beta of 2.02. The stock’s 50 day moving average price is $2.43 and its two-hundred day moving average price is $2.32.
Wall Street Analyst Weigh In
Several analysts have commented on NRXP shares. Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. BTIG Research reiterated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. D. Boral Capital reiterated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. Finally, Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.25.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares during the last quarter. Anson Funds Management LP boosted its holdings in NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares during the last quarter. Commonwealth Equity Services LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter valued at approximately $994,000. Geode Capital Management LLC raised its holdings in NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after buying an additional 33,004 shares during the period. Finally, State Street Corp raised its holdings in NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after buying an additional 10,700 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.
Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.
Read More
- Five stocks we like better than NRx Pharmaceuticals
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
